Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Laparoscopic sleeve gastrectomy (LSG) is an emerging treatment modality among the various types of surgical approach to obesity (1). The incidence of PONV in obese patients undergoing bariatric surgery, who did not receive antiemetic prophylaxis, is high at nearly 70-80 % (2,3). Postoperatively, bariatric patients appear to suffer from nausea and vomiting more frequently than normal weight or obese patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Aprepitant; BB 1101; Dexamethasone; Dexamethasone acetate; Fosaprepitant; Mirtazapine

Criteria

Inclusion Criteria:

• ASA physical status I or II

• Body mass index (BMI) ≥ 35 kg/cm-2

Exclusion Criteria:

• Patients with gastrointestinal disorders,

• Patients with significant major organ disease,

• Patients received antidepressant drugs,

• Patients received an anti-emetic drug within 48 h before surgery,

• Patients on treatment with systemic glucocorticoids within 4 weeks before surgery.